NasdaqGS:CBAY

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. More Details


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has CymaBay Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CBAY's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

7.6%

CBAY

-2.3%

US Pharmaceuticals

-1.4%

US Market


1 Year Return

68.7%

CBAY

9.2%

US Pharmaceuticals

17.8%

US Market

Return vs Industry: CBAY exceeded the US Pharmaceuticals industry which returned 10.9% over the past year.

Return vs Market: CBAY exceeded the US Market which returned 18.5% over the past year.


Shareholder returns

CBAYIndustryMarket
7 Day7.6%-2.3%-1.4%
30 Day29.5%-1.0%4.7%
90 Day90.2%-1.8%8.2%
1 Year68.7%68.7%12.1%9.2%20.5%17.8%
3 Year-2.9%-2.9%21.4%12.4%42.2%32.7%
5 Year406.1%406.1%35.1%19.2%83.4%62.7%

Price Volatility Vs. Market

How volatile is CymaBay Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is CymaBay Therapeutics undervalued compared to its fair value and its price relative to the market?

3.47x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CBAY's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CBAY's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CBAY is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: CBAY is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CBAY's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CBAY is overvalued based on its PB Ratio (3.5x) compared to the US Pharmaceuticals industry average (3.1x).


Next Steps

Future Growth

How is CymaBay Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

0.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CBAY is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CBAY is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CBAY is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if CBAY's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if CBAY's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CBAY's Return on Equity is forecast to be high in 3 years time


Next Steps

  • Explore growth companies in the Pharmaceuticals & Biotech industry.

Past Performance

How has CymaBay Therapeutics performed over the past 5 years?

-36.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CBAY is currently unprofitable.

Growing Profit Margin: CBAY is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CBAY is unprofitable, and losses have increased over the past 5 years at a rate of 36.1% per year.

Accelerating Growth: Unable to compare CBAY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CBAY is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.6%).


Return on Equity

High ROE: CBAY has a negative Return on Equity (-48.01%), as it is currently unprofitable.


Next Steps

Financial Health

How is CymaBay Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: CBAY's short term assets ($174.1M) exceed its short term liabilities ($9.5M).

Long Term Liabilities: CBAY's short term assets ($174.1M) exceed its long term liabilities ($1.5M).


Debt to Equity History and Analysis

Debt Level: CBAY is debt free.

Reducing Debt: CBAY has no debt compared to 5 years ago when its debt to equity ratio was 22.2%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CBAY has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: CBAY has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 31.6% each year


Next Steps

Dividend

What is CymaBay Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CBAY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CBAY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CBAY's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CBAY's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CBAY's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.6yrs

Average management tenure


CEO

Sujal Shah (47 yo)

3.58yrs

Tenure

US$2,556,474

Compensation

Mr. Sujal A. Shah has been the Chief Executive Officer and President of Cymabay Therapeutics, Inc, since November 6, 2017. Mr. Shah served as an Interim Chief Executive Officer and Interim President of Cym ...


CEO Compensation Analysis

Compensation vs Market: Sujal's total compensation ($USD2.56M) is above average for companies of similar size in the US market ($USD1.93M).

Compensation vs Earnings: Sujal's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Sujal Shah
President3.58yrsUS$2.56m0.17%
$ 1.0m
Charles McWherter
Senior VP & Chief Scientific Officer7.75yrsUS$1.51m0.022%
$ 125.2k
Klara Dickinson-Eason
Chief Regulatory & Compliance Officer1.75yrsUS$1.24m0%
$ 0
Daniel Menold
Vice President of Finance3.5yrsUS$857.26k0%
$ 0
Paul Quinlan
General Counselno dataUS$2.96m0%
$ 0
Ken Boehm
Senior Vice President of Human Resources0.25yrno datano data
Patrick O'Mara
Senior Vice President of Business Development3.75yrsno datano data
Robert Martin
Senior Vice President of Manufacturing & Nonclinical Development5.5yrsno datano data

3.6yrs

Average Tenure

57yo

Average Age

Experienced Management: CBAY's management team is considered experienced (3.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Sujal Shah
President3.58yrsUS$2.56m0.17%
$ 1.0m
Paul Truex
Independent Director4.5yrsUS$208.49k0%
$ 0
Kurt von Emster
Independent Director11.5yrsUS$208.49k0.16%
$ 904.5k
Jerrold Olefsky
Member of Clinical Advisory Board and Member of Scientific Advisory Boardno datano datano data
Caroline Loewy
Independent Director3.83yrsUS$198.49k0%
$ 0
Mayer Davidson
Member of Clinical Advisory Boardno datano datano data
Robert Sherwin
Member of Clinical Advisory Boardno datano datano data
Morris Birnbaum
Member of Scientific Advisory Boardno datano datano data
Steven Shoelson
Member of Scientific Advisory Boardno datano datano data
Robert Gelfand
Member of Clinical Advisory Boardno datano datano data
David Orloff
Member of Clinical Advisory Boardno datano datano data
Robert Wills
Independent Chairman5yrsUS$225.99k0.044%
$ 250.5k

4.5yrs

Average Tenure

53yo

Average Age

Experienced Board: CBAY's board of directors are considered experienced (4.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

CymaBay Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: CymaBay Therapeutics, Inc.
  • Ticker: CBAY
  • Exchange: NasdaqGS
  • Founded: 1988
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$575.207m
  • Shares outstanding: 68.89m
  • Website: https://www.cymabay.com

Number of Employees


Location

  • CymaBay Therapeutics, Inc.
  • 7575 Gateway Boulevard
  • Suite 110
  • Newark
  • California
  • 94560
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CBAYNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJan 2014
C0IDB (Deutsche Boerse AG)YesCommon StockDEEURJan 2014
0I5PLSE (London Stock Exchange)YesCommon StockGBUSDJan 2014

Biography

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MB ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/21 23:56
End of Day Share Price2020/10/21 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.